- | Vaxart
The next generation Covid-19 vaccines seeking a slice of the market
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
- | Palisade Bio
Accelerating Return of Gastrointestinal Function After Major Surgery with Tom Hallam Palisade Bio
Tom Hallam PhD is CEO of Palisade Bio a late stage biopharmaceutical company with a focus on gastrointestinal complications from major surgery and getting patients out of the hospital more quickly. With discoveries about how digestive enzymes can hurt a patient’s gastrointestinal tract, their lead asset LB1148 is a liquid that the patient drinks prior to surgery. This drug coats the entire gastrointestinal tract and inhibits digestive enzymes preventing them from attacking underlying tissue.
- | Clene Nanomedicine
Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics
Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to enhance cellular energy production.
- | Selecta Biosciences
Challenges and opportunities in gene therapy development
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
- | Orasis Pharmaceuticals
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals CEO and founder Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
- | Valneva
Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French vaccine specialist.
- | Sporos Bioventures
Stellanova, a ‘new star’ in the biotech constellation, hopes for bright future with $15.5M series A
The Houston-based preclinical biotech has raised a $15.5 million series A round led by Sporos Bioventures. The funding will go toward bringing Stellanova’s lead antibody into the clinic, building out a discovery platform and growing the team, including leadership hires later this year.
- | Scynexis
Scynexis clinches FDA green light for vaginal yeast infection blockbuster-to-be
The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class of antifungal drugs in more than 20 years and propels Scynexis into the commercial realm with a potential blockbuster in tow.
